Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122518) titled 'A single-arm, single-center phase II clinical study of luconosatuzumab combined with toripalimab in the treatment of advanced gastric cancer or gastroesophageal junction cancer that failed first-line immunotherapy' on April 14.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Huadong Hospital Affiliated to Fudan University
Condition:
Stomach cancer or cancer of the gastroesophageal junction
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-14
Target Sample Size: Test group:33;
Countries of Recruitment:
China
To know more, visit https://www.chic...